Immunotherapy for Stomach and Gastro-Oesophageal Cancer — Who It Actually Applies To

Most are not. Immunotherapy has no routine role in early stomach cancer that can be removed by surgery. That is treated with surgery and chemotherapy. The defined role is in advanced, recurrent or metastatic gastric and gastro-oesophageal junction adenocarcinoma — and even there, eligibility depends on biomarker results from the biopsy.

Two things are being decided at once, and it helps to separate them. Stage decides whether immunotherapy is on the table at all. Biomarkers decide whether it belongs in the plan for this particular tumour. A patient can clear the first test and fail the second.

Site matters less than most people expect. Cancer of the stomach and cancer of the gastro-oesophageal junction — where the food pipe meets the stomach — are handled together in NCCN and ESMO guidance, because the commonest type, adenocarcinoma, behaves similarly at both sites. Squamous cell cancer of the oesophagus sits in a separate chapter with its own rules, so a report that says “squamous” changes which guidance applies.

Medical history rules some patients out regardless of the tumour. Active autoimmune disease, a previous organ transplant, or ongoing high-dose steroids can make immunotherapy unsuitable or higher-risk, because it works by loosening restraints on the immune system rather than attacking the tumour directly.

There is a regional point worth stating plainly. Stomach cancer is one of the commoner cancers in India, and ICMR’s National Cancer Registry Programme has recorded particularly high rates in the north-eastern states. A large share of patients here are diagnosed once the disease is already advanced. That means the advanced-disease group — the group where this question even arises — is bigger in India than the word “advanced” suggests. It does not mean the biomarker tests can be skipped.

Nothing on this page decides eligibility. That rests on the histology report, the stage, previous treatment and overall fitness, read together by a medical oncologist.

Yes — more than almost anything else on the report. MMR/MSI status can make immunotherapy an option in its own right. PD-L1, reported as a CPS score, decides whether immunotherapy is added to first-line chemotherapy. HER2 status sets the backbone of the plan and changes which combination is used. These are three separate tests.

Stomach cancer is unusual in how many overlapping tests sit on one biopsy report, and they are easy to confuse. The table sets out what each one actually changes.

All of these run on the same paraffin block taken at endoscopy. Requesting them together is the difference between one turnaround and three, and it avoids a repeat endoscopy when the block runs out of tissue.

It is an addition, not a replacement. For a defined subgroup of advanced gastric and gastro-oesophageal adenocarcinoma, NCCN and ESMO recommend adding checkpoint inhibitor immunotherapy to first-line chemotherapy. The intent is deeper and longer-lasting disease control in the patients who respond. The benefit is concentrated in higher PD-L1 expression and in MSI-High disease.

What “benefit” means here is worth spelling out. In the patients who do respond, the disease shrinks or stops growing, and in some that control lasts longer than it would with chemotherapy alone. Not everyone responds. Some patients progress despite treatment, which usually shows on the first assessment scan rather than in how they feel.

You will not find a survival figure on this page, and you should be wary of one anywhere else. Outcomes vary by biomarker group, stage, fitness and the treatment setting, and a number lifted from a trial population is a poor guide to one person’s case. What is reasonable is to ask your oncologist what the current NCCN or ESMO version says for your specific biomarker group, and to note the date of the version being used.

Where the markers are absent, guidance is cautious for a reason. In tumours with low PD-L1 expression and no mismatch-repair deficiency, the added benefit of immunotherapy is small or unclear. Adding it anyway means adding immune-related side effects and cost without a clear reason to expect a gain. Declining it in that situation is a legitimate, guideline-consistent decision, not giving up.

Cost belongs in the conversation. Immunotherapy adds substantially to the cost of a treatment plan in India. Any estimate you are given should be indicative only, as of August 2026, and should state how many cycles it covers, because a per-cycle figure and a full-course figure are very different numbers.

Side effects are the other half of the trade. Added to chemotherapy, immunotherapy brings a separate set of immune-related reactions. In upper-GI cancer this needs care, because loose motions, nausea and poor appetite can come from the cancer, the chemotherapy, or an immune reaction in the bowel — and they are not managed the same way. New or worsening symptoms are reported to the treating team rather than handled at home.

• Early, operable stomach cancer — surgery is the treatment that removes the cancer, usually with chemotherapy before and after the operation. Immunotherapy is not a routine part of this plan. This is the largest group of patients who ask about it and are told it does not apply.
• Gastro-oesophageal junction and oesophageal cancer after chemoradiation and surgery — where cancer is still present in the tissue removed at surgery, guidance describes a defined role for immunotherapy afterwards. It is a specific scenario, not a general rule for early disease.
• Advanced or metastatic disease, first-line — chemotherapy remains the backbone. Checkpoint inhibitor immunotherapy is added for defined biomarker groups, and HER2-positive disease adds HER2-targeted antibody therapy on top. This is where most of the eligibility discussion happens.
• MSI-High or mismatch-repair-deficient disease — handled separately at any of the points above. Guidance gives immunotherapy a stronger role here, in some settings without chemotherapy alongside it. This is why the MMR/MSI result is worth chasing.
• Later lines, after the disease progresses — options narrow, and immunotherapy after previous immunotherapy is not an automatic next step. This is a reasonable point to ask about clinical trials. Trials are explained and searched for; no one can promise enrolment or a result.

Deciding not to add immunotherapy is a real option and is sometimes the guideline-consistent one. It should be stated as a decision with reasons, not left as something that was never discussed.

• Eating is harder in stomach and gastro-oesophageal cancer than in almost any other diagnosis, and the practical advice written for the neighbouring cancers transfers directly — Eating and Nutrition on Immunotherapy for Head and Neck Cancer covers small frequent meals, protein and swallowing difficulty.
• Tobacco is a shared risk factor across the whole upper GI tract, and patients ask what continuing it does during treatment — Tobacco Use and Immunotherapy Response sets out what is known and what is not.
• Adding immunotherapy to another class of drug is not unique to stomach cancer. For a worked example of the same idea elsewhere, see Immunotherapy Plus Targeted Therapy for Kidney Cancer.
• For how immunotherapy is delivered, monitored and paid for across our centres, see Immunotherapy at CION Cancer Clinics.

Still unsure how any of this applies to a specific stomach or gastro-oesophageal cancer diagnosis? Book a free consultation and a medical oncologist will go through the reports with you.